

# PHARMACY UPDATE

## Palivizumab (Synagis<sup>®</sup>) Clinical Drug Review Program (CDRP) Process

As respiratory syncytial virus (RSV) season approaches, Medicaid pharmacy providers should be aware that prescriptions obtained for palivizumab are subject to Clinical Drug Review Program (CDRP) prior authorization requirements. Prior authorization requirements are intended to ensure that utilization of prescriptions written for RSV occur within the RSV season and for children less than two years of age at the onset of the RSV season.

- Prescriptions for children less than two years of age at the onset of the RSV season may be dispensed and billed (on-line) between October 16 and March 31 without prior authorization.
- Prescriptions obtained between April 1 and October 15 requires prior authorization.
- Prescriptions obtained for children two years of age and over at the onset of RSV season require prior authorization.\*

Prior authorizations must be initiated by the prescriber by calling (877) 309-9493 and following the appropriate prompts. Prescription refills are limited to four per patient.

**Pharmacy providers must submit POS claims at the time of dispensing to ensure appropriate payment.**

The CDRP Prescriber worksheet and Instructions provide step-by-step assistance in completing the prior authorization process.

For clinical information on bronchiolitis, please visit:

[http://www.health.ny.gov/health\\_care/medicaid/program/prescriber\\_education/presc-educationprog.htm](http://www.health.ny.gov/health_care/medicaid/program/prescriber_education/presc-educationprog.htm)

\*The Department of Health determines RSV season based on information from the CDC.

For Medicaid Pharmacy prior authorization program questions, please call (877) 309-9493. For billing questions, please call the eMedNY Call Center at (800) 343-9000.